RedHill Biopharma Ltd. Appoints Key Opinion Leader Professor David Y. Graham from Baylor College of Medicine, Houston, Texas, as Lead Investigator for the US Pivotal Clinical Trial with RedHill's Crohn's Drug - RHB-104

Published: Oct 10, 2011

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE:RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage patented new formulations and combinations of existing drugs, announced the appointment of Professor David Y. Graham, MD, as the lead investigator of the Company's planned pivotal US clinical trial with RHB-104, its proprietary therapy for Crohn's disease. In this role, Prof. Graham will have broad responsibilities in the design of the clinical trial and will be actively involved in its execution and in the publication of its results.

Back to news